Callisto Discusses Encouraging Anti-Tumor Responses of Drug Candidate Atiprimod on BiomedDiscoveries.com; Company CEO Outlines Additional Clinical Development Plans for Drug Candidate to Target Carcinoid Cancer.LOS ANGELES Los Angeles (lôs ăn`jələs, lŏs, ăn`jəlēz'), city (1990 pop. 3,485,398), seat of Los Angeles co., S Calif.; inc. 1850. -- BiomedDiscoveries.com, http://www.BiomedDiscoveries.com, the online source for exclusive investor information in the biotechnology sector, announced today the availability of a new online Q&A-format interview with Dr. Gary S. Jacob, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. and Chief Scientific Officer of Callisto Pharmaceuticals Inc. (AMEX AMEX See: American Stock Exchange :KAL) (FWB (Fixed Wireless Broadband) See fixed wireless. :CA4), a developer of new drug therapies in the fight against cancer and other serious health threats. In the interview, Dr. Jacob discusses the Company's exciting recent announcement about one of its cancer-fighting drug candidates, Atiprimod. This anti-cancer candidate has been in clinical development to treat patients with an advanced hematological hematological, hematologic pertaining to or emanating from blood cells. hematological tests total and differential white cell counts, hematocrit estimation, erythrocyte count. cancer called Multiple Myeloma multiple myeloma A malignant proliferation of abnormal plasma cells that populate the marrow-containing bones of the body. The affected plasma cells produce myeloma protein, a monoclonal antibody that replaces normal antibodies in the blood, thereby increasing susceptibility . But the Company recently announced that Atiprimod also has demonstrated an encouraging response against metastatic Metastatic The term used to describe a secondary cancer, or one that has spread from one area of the body to another. Mentioned in: Coagulation Disorders metastatic pertaining to or of the nature of a metastasis. carcinoid carcinoid /car·ci·noid/ (kahr´si-noid) a yellow circumscribed tumor arising from enterochromaffin cells, usually in the gastrointestinal tract; the term is sometimes used to refer specifically to the gastrointestinal tumor tumors. The findings provide Callisto with an additional development path for Atiprimod as well to as potentially present new hope for patients with advanced carcinoid tumors, for which no effective drug therapy currently exists on the market. "The results from the Phase I/IIa trial of Atiprimod in advanced cancer patients have transformed our Atiprimod development program... we intend to push forward aggressively with further clinical evaluation clinical evaluation Medtalk An evaluation of whether a Pt has symptoms of a disease, is responding to treatment, or is having adverse reactions to therapy of Atiprimod in a larger population of carcinoid patients," Dr. Jacob said in the interview. "This development path could potentially result in Callisto getting its first approved drug into the market much sooner than we had originally hoped." The interview, available free of charge to all interested investors, can be accessed by visiting: http://www.BiomedDiscoveries.com. About Callisto Pharmaceuticals, Inc. Callisto is a biopharmaceutical company focused on the development of new drugs to treat various forms of cancer and other serious afflictions. Callisto's drug candidates in development currently include anti-cancer agents in clinical development, in addition to drugs for a range of other significant health care market segments, including biodefense. One of the Company's lead drug candidates, L-Annamycin, is being developed as a treatment for forms of relapsed leukemia, a currently incurable blood cancer. Callisto initiated a clinical trial of L-Annamycin in relapsed acute lymphoblastic leukemia acute lymphoblastic leukemia n. Abbr. ALL Lymphoblastic leukemia occurring mainly in older adults, characterized by rapid onset and progression of symptoms. Also called acute lymphocytic leukemia. patients in 4Q 2005. L-Annamycin, a new compound from the anthracycline family of proven anti-cancer drugs, has a novel therapeutic profile, including activity against resistant diseases and significantly reduced cardiotoxicity, or damage to the heart, compared to currently available drug alternatives. Another anti-cancer drug, Atiprimod, is in development to treat relapsed multiple myeloma, a blood cancer. Atiprimod has entered Phase I/IIa human clinical trials in relapsed multiple myeloma patients. Callisto also has drugs in preclinical development for gastrointestinal inflammation, and a program focused on the development of a drug to protect against staphylococcus staphylococcus (stăf'ələkŏk`əs), any of the pathogenic bacteria, parasitic to humans, that belong to the genus Staphylococcus. The spherical bacterial cells (cocci) typically occur in irregular clusters [Gr. and streptococcus streptococcus (strĕp'təkŏk`əs), any of a group of gram-positive bacteria, genus Streptococcus, some of which cause disease. biowarfare agents. Callisto has exclusive worldwide licenses from AnorMED Inc. and M.D. Anderson Cancer Center to develop, manufacture, use and sell Atiprimod and L-Annamycin, respectively. For investor-specific information about Callisto, including recent news and stock price data, please visit http://www.trilogy-capital.com/tcp/callisto/. For an Investor Fact Sheet about Callisto, please visit http://www.trilogy-capital.com/tcp/callisto/factsheet.html. To view an informational presentation of the Company's development pipeline of drug candidates, visit http://www.trilogy-capital.com/tcp/callisto/powerpoint.html. Callisto is also listed on the Frankfurt Stock Exchange Frankfurt Stock Exchange The largest of Germany's eight securities exchanges, operated by Deutsche Borse AS. under the ticker symbol Ticker Symbol An arrangement of characters (usually letters) representing a particular security listed on an exchange or otherwise traded publicly. When a company issues securities to the public marketplace, it selects an available ticker symbol for its securities which investors CA4. For additional information, visit www.callistopharma.com. About BiomedDiscoveries.com BiomedDiscoveries.com provides exclusive commentary, research, interviews and other information about the smallcap investment marketplace. BiomedDiscoveries.com strives to provide investors with information and research-based data regarding important individual companies and overall marketplace trends. Resources available on BiomedDiscoveries.com include audio interviews with corporate leaders and respected commentators, as well as technical white papers and other forms of market and investment analysis. It is located at http://www.BiomedDiscoveries.com. Forward-Looking Statements Statements made on BiomedDiscoveries.com may contain forward-looking statements made by senior management of the companies presented here that involve risks and uncertainties, such as statements about plans, objectives, expectations, assumptions or future events. These statements involve estimates, assumptions, known and unknown risks, uncertainties and performances, or achievements expressed or implied by the forward-looking statements. Actual future results and trends may differ materially from those made in -- or suggested by -- statements presented here due to a variety of factors. Consequently, you should not place undue reliance on any forward-looking statements made here. Many of these and other risks and uncertainties are discussed in greater detail in recent filings with the Securities Exchange Commission for the companies that are presented by BiomedDiscoveries.com. Compensation and Other Disclosures BiomedDiscoveries.com is a wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. of Trilogy Capital Partners, Inc. Trilogy Capital Partners provides investor relations Investor relations The process by which the corporation communicates with its investors. services to public companies. The companies presented by BiomedDiscoveries.com are usually clients of Trilogy Capital Partners and compensate Trilogy Capital Partners for these services, including cash compensation and equity securities. In addition, Trilogy Capital Partners and its affiliates may own securities of the presenting companies, and may from time to time purchase and sell securities of these companies in the open market or in private transactions. Callisto pays $12,500 per month through July 2006 and thereafter for so long as Trilogy is retained to provide investor relations services. In connection with its engagement, Trilogy received non-transferable warrants from this company to purchase 1,793,322 shares of common stock for $1.03 per share expiring in July 2008, provided that the warrants are not exercisable to the extent that following exercise Trilogy would beneficially own 5% or more of the outstanding common stock of the company. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion